Literature DB >> 17315216

The SOCS-1 gene methylation in chronic myeloid leukemia patients.

Ozden Hatirnaz1, Umit Ure, Cem Ar, Cemaliye Akyerli, Teoman Soysal, Burhan Ferhanoğlu, Tayfun Ozçelik, Ugur Ozbek.   

Abstract

SOCS-1, an important protein in the JAK/STAT pathway, has a role in the down stream of BCR-ABL protein kinase. We investigated 56 CML patients and 16 controls for the methylation status of SOCS-1 gene promoter and Exon 2 regions. Exon 2 was found to be methylated in 58.9% of the patients and 93.8% of the controls [P = 0.020, OR = 0.121(0.015-0.957)%95CI]. The promoter region was found unmethylated in all patient samples and controls. Although previous studies revealed a relation between SOCS1 gene Exon-2 hypermethylation and CML development or progression, the results of this study showed no such correlation. On the contrary, our results might be indicating hypomethylation in CML patients, this hypothesis need to be studied in larger study population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17315216     DOI: 10.1002/ajh.20886

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  18 in total

1.  Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis.

Authors:  R C Sobti; Neha Singh; Showket Hussain; Vanita Suri; Raje Nijhawan; A C Bharti; Mausumi Bharadwaj; B C Das
Journal:  Cell Oncol (Dordr)       Date:  2011-09-21       Impact factor: 6.730

2.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

3.  A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.

Authors:  Xiaoxue Qiu; Guijie Guo; Ke Chen; Masaki Kashiwada; Brian J Druker; Paul B Rothman; Ji-Long Chen
Journal:  Neoplasia       Date:  2012-06       Impact factor: 5.715

4.  Expression of SOCS-1 in the liver tissues of chronic hepatitis B and its clinical significance.

Authors:  Zhi-Xin Zhao; Qing-Xian Cai; Xiao-Mou Peng; Yu-Tian Chong; Zhi-Liang Gao
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

5.  Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Authors:  Hannes Neuwirt; Martin Puhr; Frédéric R Santer; Martin Susani; Wolfgang Doppler; Gemma Marcias; Veronika Rauch; Maria Brugger; Alfred Hobisch; Lukas Kenner; Zoran Culig
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

Review 6.  The role of suppressors of cytokine signalling in human neoplasms.

Authors:  Walid Sasi; Anup K Sharma; Kefah Mokbel
Journal:  Mol Biol Int       Date:  2014-03-16

Review 7.  The diagnostic value of DNA methylation in leukemia: a systematic review and meta-analysis.

Authors:  Danjie Jiang; Qingxiao Hong; Yusheng Shen; Yan Xu; Huangkai Zhu; Yirun Li; Chunjing Xu; Guifang Ouyang; Shiwei Duan
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

8.  SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression via interaction with DP-1.

Authors:  Yoshikazu Masuhiro; Kenichi Kayama; Akie Fukushima; Koji Baba; Makio Soutsu; Yoshiaki Kamiya; Michio Gotoh; Noboru Yamaguchi; Shigemasa Hanazawa
Journal:  J Biol Chem       Date:  2008-08-07       Impact factor: 5.157

Review 9.  Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

Authors:  Alessandro M Vannucchi; Paola Guglielmelli; Alessandro Rambaldi; Costanza Bogani; Tiziano Barbui
Journal:  J Cell Mol Med       Date:  2009-06-11       Impact factor: 5.310

10.  Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.

Authors:  Hamid Ali Nagi Al-Jamal; Siti Asmaa Mat Jusoh; Rosline Hassan; Muhammad Farid Johan
Journal:  BMC Cancer       Date:  2015-11-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.